Analysts think ACHV stock price could increase by 186%
Aug 01, 2024, 6:27 AM
-12.40%
What does ACHV do
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company based in Seattle, is developing cytisinicline, a plant-based alkaloid aimed at aiding smoking cessation through its dual-acting mechanism as both an agonist and antagonist. Cytisinicline targets the alpha-4 beta-2 nicotinic acetylcholine receptors in the brain to alleviate nicotine cravings and withdrawal symptoms, positioning it as a potential improvement over current prescription and OTC cessation aids.
9 analysts think ACHV stock price will increase by 185.60%. The current median analyst target is $14.28 compared to a current stock price of $5.00. The lowest analysts target is $10.10 and the highest analyst target is $31.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.